Charleston, SC -- (SBWIRE) -- 12/19/2013 -- Hot Shot Stock Alerts is a market and commodities news and marketing web service, providing investing news, business news, headline news, news alerts, personal finance, stock market, and press releases. Hot Shot Stock Alerts carries you the most fascinating reviews and research reports regarding following stocks: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC), Novavax, Inc. (NASDAQ:NVAX)
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) closed latest trading day at $4.98, up +19.71%, on volume of over 45.81 million shares. The stock went up +22.36% in the last 5 days. Its average trading volume is 20.76 million shares. In the time frame of the last one month, the share-price has surged almost +91.54%. Its market capitalization was $924.57 million.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients.
What was the Moving Force behind ARIA On Bullish Run? Read This Research Report
With the latest rise of +5.01%, Gilead Sciences, Inc. (NASDAQ:GILD) now has YTD performance +100.41% which for the week is positive at +4.22%. The total number of shares traded on the latest trading day was about 1,200 shares, and changed hands at price range of $70.62 to $73.68 apiece. The company ended previous trading at $73.59.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia.
For How Long GILD will Fight for Profitability? Read This Trend Analysis report
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) reported the price of the stock declined -12.01% and finished the day at $0.740 on below average volume. The total number of shares traded on the latest trading day was about 10.35M shares, and changed hands at price range of $0.65 to $0.79 apiece. The shares declined about -70.87% since the start of year and has a -72.79% lost in last three months. Narrowing down the performance period, the stock fell -70.75% for the month and a -72.79% drop over the week.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, engages in developing and commercializing immune-based therapies for the treatment of brain, ovarian, and other solid tumors.
Has IMUC Found The Bottom And Ready To Gain Momentum? Find Out Here
Novavax, Inc. (NASDAQ:NVAX) ended previous trading at $4.51, gaining +0.89%. The total number of shares traded on the latest trading day was about 5.93M shares. In the last 5 days it showed a recovery of +6.62% and on its one month graph, shares are +47.87% up. The stock has a 52-week high price of $4.65 and its 52-week low was recorded at $1.68.
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company’s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines.
Will NVAX Continue To Move Higher? Find Out Here
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list.
Never invest into a stock discussed on this web site or the HotShotStockAlerts.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
HotShotStockAlerts.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Read full Disclaimer at: http://hotshotstockalerts.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)